12:00 AM
Jan 17, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Status

GSK1605786: Phase III started

GlaxoSmithKline began a double-blind, placebo-controlled, international Phase III trial to evaluate 500 mg GSK1605786 given once or twice daily in about 600 patients. Last year, GSK exercised its option...

Read the full 123 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >